



LINCOLN PHARMACEUTICALS LIMITED



Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060.

CIN: L24230GJ1995PLC024288, Ph. No.: +91-79-4107-8000, Fax: +91-79-4107-8062,

Website: www.lincolnpharma.com, E-Mail: info@lincolnpharma.com.

LINCOLN
PHARMACEUTICALS LTD.
HEALTHCARE FOR ALL

LINCOLN
PHARMACEUTICALS LTD.
HEALTHCARE FOR ALL

Statement of Standalone and Consolidated Un-Audited Financial Results for the Quarter and Nine-Months Ended on 31-December-2018.

PART-I													(Rs. In Lakhs)
Sr. No.	Particulars	Standalone						Consolidated					
		Quarter Ended		Nine-Months Ended		Year Ended	Quarter Ended		Nine-Months Ended		Year Ended		
		31/12/2018 (Un-Audited)	30/09/2018 (Un-Audited)	31/12/2017 (Un-Audited)	31/12/2018 (Un-Audited)	31/12/2017 (Un-Audited)	31/03/2018 (Audited)	31/12/2018 (Un-Audited)	30/09/2018 (Un-Audited)	31/12/2017 (Un-Audited)	31/12/2018 (Un-Audited)	31/12/2017 (Un-Audited)	31/03/2018 (Audited)
1	Income												
	A) Revenue From Operations	8,100.18	9,794.85	7,555.78	27,558.20	24,894.50	32,551.19	8,443.49	10,260.36	8,018.41	28,686.01	29,451.25	36,163.71
	B) Other Income	53.47	439.47	273.71	716.97	820.16	580.38	37.97	443.18	283.42	652.31	459.70	545.37
	Total Income	8,153.65	10,234.33	7,829.49	28,275.17	25,714.66	33,131.57	8,481.46	10,703.54	8,301.83	29,338.32	29,910.95	36,709.08
2	Expenses												
	A) Cost of Material Consumed	1,466.42	2,700.98	1,687.28	5,983.71	4,697.15	6,359.23	2,445.99	3,563.23	2,461.24	8,664.16	6,684.76	9,155.30
	B) Purchase of Stock-In-Trade	2,244.76	2,208.08	2,085.88	6,693.75	8,500.82	10,686.23	1,326.98	1,339.42	1,551.18	3,757.31	9,705.88	10,393.98
	C) Changes In Inventories of Finished Goods, Stock-In-Trade and WIP	55.26	372.09	(318.63)	848.26	529.28	70.65	(106.99)	386.34	(424.34)	1,002.64	358.89	(297.61)
	D) Excise Expenses	NIL	NIL	NIL	NIL	55.76	55.76	NIL	NIL	NIL	NIL	123.37	102.28
	E) Employee Benefits Expenses	1,385.39	1,183.55	1,425.37	3,837.98	3,739.00	4,750.80	1,469.90	1,273.07	1,513.32	4,095.00	3,968.47	5,114.78
	F) Finance Costs	77.40	145.92	94.66	305.18	315.19	426.47	70.87	175.43	136.78	321.07	447.15	541.10
	G) Depreciation and Amortisation Expense	148.92	107.32	96.50	370.06	329.52	439.93	193.92	150.83	139.43	502.77	458.12	611.18
	H) Other Expenses	1,648.20	1,720.57	1,203.90	5,118.16	4,019.40	6,032.69	1,946.64	1,789.63	1,302.09	5,567.91	4,343.21	6,463.36
	Total Expenses	7,026.35	8,438.52	6,274.96	23,157.10	22,186.12	28,821.77	7,347.31	8,677.95	6,679.70	23,910.86	26,089.85	32,084.37
3	Profit / (Loss) Before Exceptional Items & Tax (1-2)	1,127.30	1,795.81	1,554.53	5,118.07	3,528.54	4,309.80	1,134.15	2,025.59	1,622.13	5,427.46	3,821.10	4,624.71
4	Exceptional Items	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
5	Profit / (Loss) after Exceptional items but Before Tax (3-4)	1,127.30	1,795.81	1,554.53	5,118.07	3,528.54	4,309.80	1,134.15	2,025.59	1,622.13	5,427.46	3,821.10	4,624.71
	Tax Expense												
	A) Current Tax (Net)	224.80	549.38	416.80	1,353.81	898.54	958.49	228.55	662.77	431.89	1,487.61	962.64	1,038.47
	B) Deferred Tax (Net)	(42.73)	(194.23)	24.41	(181.96)	73.04	75.66	(8.67)	(138.02)	31.87	(82.69)	76.14	121.30
7	Profit / Loss For The Period (5-6)	945.24	1,440.66	1,113.32	3,946.22	2,556.96	3,275.65	914.27	1,500.84	1,158.37	4,022.54	2,782.32	3,464.94
	Attributable to:												
	Non-Controlling Interest	NIL	NIL	NIL	NIL	NIL	NIL	(0.41)	0.85	0.64	1.08	3.19	2.79
	Owners of the Company	945.24	1,440.66	1,113.32	3,946.22	2,556.96	3,275.65	914.68	1,499.99	1,157.73	4,021.46	2,779.13	3,462.15
9	Other Comprehensive Income (Net Of Tax)	2.30	2.31	(1.56)	6.90	(4.66)	9.20	2.48	2.47	(1.50)	7.41	(4.48)	9.87
10	Total Comprehensive Income	947.54	1,442.97	1,111.76	3,953.12	2,552.30	3,284.85	917.16	1,502.46	1,156.23	4,028.87	2,774.65	3,472.02
11	Paid-Up Equity Share Capital (Face Value Of Rs. 10/- Each)	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00
12	Other Equity						19,954.03						20,454.44
13	Earnings Per Share (of Rs. 10/- Each) (Not Annualised)												
	(a) Basic	4.73	7.20	5.57	19.73	12.78	16.38	4.57	7.50	5.79	20.11	13.90	17.31
	(b) Diluted	4.73	7.20	5.57	19.73	12.78	16.38	4.57	7.50	5.79	20.11	13.90	17.31

NOTES:	
1	The Financial Results of the Company for the Quarter Ended December 31, 2018 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company in their meeting held on February 12, 2019. The Statutory Auditors of the Company have carried out Limited Review of these Results and the Results are being Published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2	The Financial Results of the Company have been prepared in accordance with Indian Accounting Standards (IND-AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules, 2016 and become mandatorily applicable to the Company with effect from April 1, 2017.
3	From the applicability of Goods and Service Tax (GST) with effect from 1 July, 2017, Revenue From Operations are disclosed Net of GST. Accordingly the Revenue From Operations and Excise Duty Expense for the Quarter and Six Months Ended September 30, 2018 are not comparable with the previous periods presented in the results.
4	The Financial Results have been prepared based on the IND-AS issued and effective on the date of adoption of the results by the board. These Financial Results may require adjustment on account of any changes in the standards or subsequent clarification (if any) as issued by the MCA.
5	The Company has adopted Ind AS 115 'Revenue from Contracts with Customers' effective April 1, 2018. Application of Ind AS 115 does not have any significant impact on retained earnings as at April 1, 2017 and Financial Results of the Company.
6	Segment reporting as defined in IND-AS 108 is not applicable, since the Company has only one reportable segment i.e. Pharmaceuticals.
7	Comparative figures have been rearranged/regrouped wherever necessary.
8	Consolidated Results includes results of its subsidiaries.
FOR LINCOLN PHARMACEUTICALS LTD.	
PLACE: AHMEDABAD DATE: FEBRUARY 12, 2019	Sd/- MAHENDRA G. PATEL MANAGING DIRECTOR DIN: 00104706